
Taysha Gene Therapies Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics
2025-11-11 16:12:35Taysha Gene Therapies, Inc. reported a net profit of USD -45.25 million for the half-year, facing ongoing profitability challenges. Despite a decrease in raw material costs, the company experienced a decline in net sales and operating cash flow, alongside notable fluctuations in stock performance over the past year.
Read full news articleNo announcement available
Corporate Actions
No corporate action available






